Successful Treatment of Severe Hidradenitis Suppurativa with Adalimumab
Authors:
M. Arenbergerová; S. Gkalpakiotis; T. Frey; P. Arenberger
Authors‘ workplace:
Dermatovenerologická klinika 3. LFUK a FNKV, Praha, přednosta prof. MUDr. Petr Arenberger, DrSc., MBA
Published in:
Čes-slov Derm, 86, 2011, No. 1, p. 18-22
Category:
Pharmacologyand Therapy, Clinical Trials
Overview
Hidradenitis suppurativa is a chronic suppurative disease characterized by inflammatory nodules, fistulas and scarring predominantly in the armpits and the groins. Systemic therapy including oral antibiotics, retinoids or antiandrogens has only limited effect, advanced stages require surgical treatment of affected areas. Recently, there were some reports of successfull therapy of hidradenitis suppurativa by TNF-α antagonists. In contrast to infliximab and etanercept, the positive effect of adalimumab was described only in small cohorts of patients. Nine patients with severe, recalcitrant hidradenitis were treated for 1 year with adalimumab in a standard regimen and followed-up for 1 year. All patients improved within 4–6 weeks and laboratory parameters like CRP and leucocyte count were reduced significantly during the treatment. In four patients we observed a long lasting improvement, five patients showed recurrences several months after the therapy discontinuation. Average recurrence-free interval was 9 months. According to our experience therapy with adalimumab is suitable for treatment and induction of long-term remission in severe hidradenitis suppurativa.
Key words:
hidradenitis suppurativa – adalimumab – TNF-α antagonist
Sources
1. BLANCO, R., MARTINEZ-TABOADA, V. M., VILLA, I., GONZÁLEZ-VELA, M. C., FERNÁNDEZ-LLACA, H., AGUDO, M., GONZÁLEZ-LÓPEZ, M. A. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch. Dermatol., 2009, 145, 5, p. 580–584.
2. BRUNASSO, A. M., DELFINO, C., MASSONE, C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br. J. Dermatol., 2008, 159, p. 761–763.
3. CUSACK, C., BUCKLEY, C. Etanercept: effective in the management of hidradenitis suppurativa. Br. J. Dermatol., 2006, 154, p. 726–729.
4. GIAMARELLOS-BOURBOULIS, EJ., PELEKANOU, E., ANTONOPOULOU, A. et al. An open-label phase II study of the safety of etanercept for the therapy of hidradenitis suppurativa. Br. J. Dermatol., 2008, 158, p. 567–572.
5. HARDE, V., MROWIETZ, U. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J. DDG., 2009, 7, p. 139–141.
6. JANSEN, T., ALTMEYER, P., PLEWIG, G. Acne inversa (alias hidradenitis suppurtiva). J. Eur. Acad. Dermatol. Venereol., 2001, 15, p. 532–540.
7. JEMEC, G. B. E., WENDELBOE, P. A randomized trial of topical clindamycin vs. systemic tetracycline in hidradenitis suppurativa. J. Am. Acad. Dermatol., 1998, 39, p. 971–974.
8. KAGAN, R. J., YAKUBOFF, K. P., WARDEN, G. D. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery, 2005, 138, p. 734–740.
9. KASAI, A., HIRAMATSU, N., HAYAKAWA, K. et al. High levels of dioxin-likepotential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res., 2006, 66, p. 7143–7150.
10. LOZERON, P., DENIER, C., LACROIX, C., ADAMS, D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch. Neurol., 2009, 66, p. 490–497.
11. MEKKES, J. R., BOS, J. D. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br. J. Dermatol., 2008, 158, p. 370–374.
12. MOUL, D. K., KORMAN, N. J. Severe hidradenitis suppurativa treated with adalimumab. Arch. Dermatol., 2006, 142, p. 1110–1112.
13. DE PAIVA, C. S., CORRALES, R. M., VILLARREAL, A. L. et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res., 2006, 83, p. 526–535.
14. PANTELEYEV, A. A., BICKERS, D. R. Dioxin-induced chloracne-reconstructing the cellular and molecular mechanisms of a classic environmental disease. Exp. Dermatol., 2006, 15, p. 705–730.
15. POULIN, Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J. Cutan. Med. Surg., 2009, 13, p. 221–225.
16. REVUZ, J. Hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol., 2009, 23, p. 985–998.
17. SCHEINFELD, N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J. Am. Acad. Dermatol., 2006, 55, p. 163–164.
18. THIELEN, A. M., BARDE, C., SAURAT, J. H. Long-term infliximab for severe hidradenitis suppurativa. Br. J. Dermatol., 2006, 154, p. 1074–1108.
19. YAMAUCHI, P. A., MAU, N. Hidradenitis suppurativa managed with adalimumab. J. Drugs Dermatol., 2009, 8, p. 181–183.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2011 Issue 1
Most read in this issue
- Successful Treatment of Severe Hidradenitis Suppurativa with Adalimumab
- Hidradenitis suppurativa
- Clinical Pathological Aspects of Pendulating Soft Fibroma
- Autoimmune Hepatitis during by Infliximab Treatment of Psoriasis: Case Report